Imbalance between interleukin‐1 agonists and antagonists: relationship to severity of inflammatory bowel disease

Interleukin (IL)‐1 is a key mediator in the pathogenesis of inflammatory bowel disease (IBD). Naturally occurring IL‐1 modulators include IL‐1 receptor antagonist (IL‐1Ra), IL‐1 soluble receptor Type I (IL‐1sRI), IL‐1sRII and IL‐1 receptor accessory protein (AcP). Systemic and mucosal levels of IL‐1 soluble receptors remain unknown in IBD. Plasma or colonic tissues were obtained from 185 consecutive unselected patients with Crohn's disease (CD) or ulcerative colitis (UC) and from 52 control subjects. Plasma and colonic explant culture supernatants were assessed for IL‐1α, IL‐1β, IL‐1Ra, IL‐1sRI and IL‐1sRII. Plasma IL‐1Ra levels were higher in UC (+93%) than in healthy subjects. IL‐1α and IL‐1β were not detected. IL‐1sRII levels were marginally lower in CD (−10%) and UC (−9%), whereas IL‐1sRI levels were elevated in CD (+28%) only. Plasma IL‐1sRI levels correlated positively (P < 0·01) with Crohn's disease activity index (r = 0·53), C‐reactive protein (r = 0·46) and α1‐acid glycoprotein (r = 0·42). In colonic explant cultures, IL‐1α and IL‐1Ra levels were elevated in non‐lesional (+233% and +185% respectively) and lesional CD (+353% and +1069%), lesional UC (+604% and +1138%), but not in non‐lesional UC. IL‐1β was elevated in lesional UC (+152%) and CD (+128%). In contrast, IL‐1sRII levels were elevated in non‐lesional CD (+65%), but remained unchanged in lesional CD, non‐lesional and lesional UC. IL‐1sRI levels did not differ between patient and control groups. These results indicate that (i) the proinflammatory moiety IL‐1sRI is a systemic marker of inflammation and activity in CD and (ii) local shedding of the functional antagonist IL‐1sRII may dampen colonic inflammation in CD, but not in UC.

[1]  H. Asakura,et al.  Influence of Interleukin-10 on the Interleukin-1 Receptor Antagonist/Interleukin-1β Ratio in the Colonic Mucosa of Ulcerative Colitis , 2001, Digestion.

[2]  C. Gabay,et al.  Physiologic role of interleukin-1 receptor antagonist , 2000, Arthritis research.

[3]  A. Whitehead,et al.  IL-1 Signaling Cascade in Liver Cells and the Involvement of a Soluble Form of the IL-1 Receptor Accessory Protein1 2 , 2000, The Journal of Immunology.

[4]  C. Dinarello,et al.  The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. , 2000, Immunology today.

[5]  D. Hommes,et al.  Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. , 2000, Current opinion in clinical nutrition and metabolic care.

[6]  G. Rogler,et al.  Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6 , 2000, Gut.

[7]  Huiying Yang,et al.  Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. , 1999, Gastroenterology.

[8]  L. Eckmann,et al.  The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. , 1998, Journal of immunology.

[9]  C. Dinarello,et al.  Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. , 1998, Arthritis and rheumatism.

[10]  C. Fiocchi,et al.  Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. , 1998, Gastroenterology.

[11]  Seidman,et al.  Colonic explant production of IL‐1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD) , 1998, Clinical and experimental immunology.

[12]  S. Nikolaus,et al.  Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation , 1998, Gut.

[13]  M. Kamm,et al.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease , 1997, The Lancet.

[14]  B. Castner,et al.  Further evidence for a common mechanism for shedding of cell surface proteins , 1997, FEBS letters.

[15]  S. Banks,et al.  Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. , 1996, Blood.

[16]  S. Paul,et al.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Dayer,et al.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. , 1995, The Journal of clinical investigation.

[18]  M. Labow,et al.  Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex (*) , 1995, The Journal of Biological Chemistry.

[19]  C. Fiocchi,et al.  Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. , 1995, Journal of immunology.

[20]  P. Young,et al.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Dower,et al.  Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. , 1994, Journal of immunology.

[22]  S. Dower,et al.  Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. , 1994, Journal of immunology.

[23]  C. Nast,et al.  Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. , 1994, The Journal of clinical investigation.

[24]  K. Mitsuyama,et al.  IL‐8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease , 1994, Clinical and experimental immunology.

[25]  R. Sartor,et al.  Cytokines in intestinal inflammation: pathophysiological and clinical considerations. , 1994, Gastroenterology.

[26]  R. Macdermott,et al.  Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease , 1993 .

[27]  C. Dinarello,et al.  Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. , 1993, JAMA.

[28]  C. Fiocchi,et al.  Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. , 1993, Gastroenterology.

[29]  C. Dinarello,et al.  The role of interleukin-1 in disease. , 1993, The New England journal of medicine.

[30]  S. Schreiber,et al.  The role of the mucosal immune system in inflammatory bowel disease. , 1992, Gastroenterology clinics of North America.

[31]  J. Symons,et al.  Purification and characterization of a novel soluble receptor for interleukin 1 , 1991, The Journal of experimental medicine.

[32]  D. Podolsky,et al.  Inflammatory bowel disease (1) , 1991, The New England journal of medicine.

[33]  C. Dinarello,et al.  Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. , 1991, Blood.

[34]  D. Dripps,et al.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. , 1991, The Journal of biological chemistry.

[35]  G. Duff,et al.  A soluble form of the interleukin‐1 receptor produced by a human B cell line , 1990, FEBS letters.

[36]  R. Horuk,et al.  Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. , 1990, The Journal of biological chemistry.

[37]  A. Cooke,et al.  Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine , 1990, Clinical and experimental immunology.

[38]  J. Dayer,et al.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[39]  C. Nast,et al.  Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. , 1990, The Journal of clinical investigation.

[40]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[41]  Y. Mahida,et al.  Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. , 1989, Gut.

[42]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[43]  Dirk E. Smith,et al.  The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. , 2003, Immunity.

[44]  A. Forbes,et al.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. , 1997, Lancet.

[45]  W. Arend.  Interleukin-1 receptor antagonist. , 1993, Advances in immunology.

[46]  S. Schreiber,et al.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. , 1993, Clinical and experimental immunology.

[47]  T. Halstensen,et al.  The mucosal immune system in inflammatory bowel disease , 1992 .

[48]  J. Chin,et al.  Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. , 1991, Arthritis and rheumatism.